November 2nd, 2026More magic in Anaheim: Highlights from AAOpt 2026What to take away on PBM, hormonal eye health, and GLP-1 receptor agonists from this year’s meeting.Read more
October 30th, 2026From Our Editorial Board: Comments From the FDA Advisory Committee meeting on SYD-101The meeting, which came a year after the agency issued a complete response letter in October 2025, was held from 8:30 AM to 3 PM ET and was open to the public.Read more
November 21st, 2026Takeaways from this week in optometry: November 16-20Yuvezzi’s Health Canada submission leads this week’s recap, plus AI front desks, the EMERALD trial, and Alberta’s scope expansion.Read more
November 20th, 2026Tenpoint Therapeutics submits NDS for Yuvezzi presbyopia drop to Health CanadaYuvezzi Health Canada submission builds on BRIO-I and BRIO-II phase 3 data.Read more
November 20th, 2026Polygenic risk flags patients likely to need more glaucoma treatment Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.Read more
November 19th, 2026First patient dosed in EMERALD trial of EO2002 for corneal edemaThe phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.Read more
November 19th, 2026High Point University optometry school earns ACOE preliminary approvalThe school will be admitting its inaugural Doctor of Optometry class in summer 2027, with full accreditation possible in 2030-31.Read more
November 18th, 2026Alice Epitropoulos, MD, on phentolamine for presbyopia treatmentThe FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.Read more